BioTwin is a technology company.
BioTwin has raised $220K across 1 funding round.
BioTwin has raised $220K in total across 1 funding round.
BioTwin has raised $220K in total across 1 funding round.
BioTwin's investors include SFC Capital.
BioTwin is a biotechnology company developing AI-powered digital twins—virtual human replicas built from biomarkers, biometrics, genetics, environment, nutrition, and lifestyle data—to enable early disease detection, prediction, prevention, and personalized medicine.[1][2][4] It serves health professionals and individuals via an at-home biomarker kit that creates a "test before the test," simulating health outcomes in a parallel virtual universe to optimize treatments, reduce costs, and avoid unnecessary screenings for conditions like oncology, allergies, diabetes, Parkinson's, and chronic fatigue.[3][4] The platform addresses imprecise diagnostics by providing continuous, complete patient health views, with current pilots in lifestyle medicine and women's health, operating from Québec City with 11-50 employees (around 20 reported) and under $10M in funding since its 2018-2019 founding.[1][3]
BioTwin emerged in Québec, Canada, around 2018-2019 as Ai-Genetika Inc., founded to tackle gaps in healthcare data where professionals rely on incomplete patient information for diagnostics and treatments.[1][3] While specific founders are not detailed in available sources, the company quickly focused on AI, biomarkers (metabolites, lipids, proteins), and biometrics to build virtual twins that learn from historical and real-time data for predictive insights.[2][4] Early traction includes ongoing pilot projects in oncology, allergies, women's health, diabetes, chronic fatigue, lifestyle medicine, and Parkinson's, positioning it as a pioneer in accessible, at-home precision health tools.[4]
BioTwin rides the digital twin wave in healthcare, accelerated by AI advancements and post-pandemic demand for remote, preventive tools amid rising chronic disease burdens.[4][6] Timing aligns with precision medicine trends, where biomarkers and multi-omics data enable hyper-personalized care, countering market forces like escalating screening costs and diagnostic errors.[1][3] It influences the ecosystem by democratizing simulations via at-home kits, fostering a "metaverse" for health experiments that could integrate with wearables and EHRs, ultimately pushing payers and providers toward value-based, risk-free models.[2][4]
BioTwin is poised to scale its pilots into broader clinical adoption, potentially expanding biomarker panels and AI models for real-time integrations with global health data networks. Trends like multimodal AI, regulatory nods for digital twins (e.g., FDA pilots), and consumer health tech will propel growth, evolving its role from niche predictor to mainstream preventive platform. As virtual twins mature, BioTwin could redefine healthcare economics, tying back to its core promise: a safer, smarter path to personalized wellness.[4][6]
BioTwin has raised $220K across 1 funding round. Most recently, it raised $220K Seed in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $220K Seed | SFC Capital |